Posted by Michael Wonder on 31 Mar 2022
ASC Therapeutics receives key regulatory designations in U.S. and Europe to advance its second generation gene therapy for haemophilia A
29 March 2022 - ASC Therapeutics has received from the U.S. FDA the fast track designation for ASC618, a second-generation gene therapy of haemophilia A.
In addition, the EMA Committee for Orphan Medicinal Products has issued a positive opinion for an orphan medical product designation of ASC618.
